OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 8.89 EUR -0.78% Market Closed
Market Cap: 193.4m EUR
Have any thoughts about
OSE Immunotherapeutics SA?
Write Note

OSE Immunotherapeutics SA
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Net Issuance of Debt
-€3.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Net Issuance of Debt
€33.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Net Issuance of Debt
-€1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-33%
G
Genfit SA
PAR:GNFT
Net Issuance of Debt
-€7.3m
CAGR 3-Years
43%
CAGR 5-Years
-36%
CAGR 10-Years
-13%
Inventiva SA
PAR:IVA
Net Issuance of Debt
€20.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Net Issuance of Debt
-€18.2m
CAGR 3-Years
-5%
CAGR 5-Years
-99%
CAGR 10-Years
N/A
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
193.5m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
28.33 EUR
Undervaluation 69%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Net Issuance of Debt?
Net Issuance of Debt
-3.6m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Net Issuance of Debt amounts to -3.6m EUR.

Back to Top